# Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

> **NCT03031470** · PHASE2 · TERMINATED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 40 (actual)

## Conditions studied

- Ischemia-reperfusion Injury in Liver Transplant
- Early Allograft Dysfunction

## Interventions

- **DRUG:** Reparixin
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT03031470
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-10
- **Primary completion:** 2017-02-09
- **Final completion:** 2017-03-31
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Taking into account that 5 out of 22 patients in the Reparixin group experienced EAD during the first stage of the study, according to the Protocol and the DMC conclusion, it was decided on the early termination of the study
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031470, "Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03031470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*